Bayer’s blockbuster pipeline promises broken by a PhII setback for top cancer drug
Bayer touted its experimental cancer drug anetumab ravtansine as a $2 billion-plus peak earner in the making for the pharma company. And it just flopped in its first mid-stage study — this one focused on rare cases of mesothelioma.
Bayer will detail the data later, but investigators say the drug flunked a Phase II study with a primary endpoint of progression free survival. The drug is also currently in 6 other early stage studies for a variety of tumor types.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.